精神分裂症基于客观评估的个体化治疗模型研究

Schizophrenia is kinds of serious mental disorder. But the treatment of schizophrenia is still in the "trial and error" stage now. The treatment process is subjective and cannot choose the appropriate drugs according to the clinical manifestations of the patients, most of them were dissatisfied with the effect of treatment. Some kinds of auditory and visual cognitive processing and development are abnormal, which are the core damage and biomarkers of schizophrenia. There is hoping to be an objective indicator of the prediction and monitoring of the curative effect. This study is based on the poupulation pharmacokinetics for the use of olanzapine system in first episode schizophrenic patients to ensure that the patient's blood concentration is in a suitable range. After prepulse suppression, high-density electroencephalogram and eye movement test, we detected the indicators related to auditory and visual cognitive processing in the first episode of schizophrenia before treatment, during treatment and after treatment. Correlation analysis with drug efficacy indicates that certain indicators or combinations of indicators can be used as biomarkers for prediction and monitoring of drug efficacy, and an objective assessment based olanzapine personalized treatment model is established. It provides a scientific basis for the individualized treatment of olanzapine.

精神分裂症是一种严重精神障碍，但目前对其的治疗仍处于“试-误”阶段，治疗过程主观性强，无法根据患者临床表现或生物分型选择合适的药物，多数患者治疗效果不满意。各类听觉及视觉认知加工发育异常，是精神分裂症的核心损伤及生物标志物，有希望成为预测及监测疗效的客观指标。本研究基于群体药代动力学理论对首发精神分裂症患者使用奥氮平系统治疗，保证患者血药浓度在适宜范围。后通过前脉冲抑制，高密度脑电图及眼球运动测查，对首发精神分裂症患者在治疗前、治疗中及治疗后的相关的听觉及视觉认知加工异常的指标进行测查。与药物疗效进行相关分析，提示某些指标或指标组合可以作为药物疗效预测与监测的生物标志物，建立基于客观评估的奥氮平个体化治疗模型。为奥氮平等抗精神病药物的个体化治疗提供科学依据。

精神分裂症是一种严重精神障碍，但目前对其的治疗仍处于“试-误”阶段，治疗过程主观性强，无法根据患者临床表现或生物分型选择合适的药物，多数患者治疗效果不满意。各类听觉视觉认知加工发育异常，是精神分裂症的核心损伤及生物标志物，有希望成为预测及监测疗效的客观指标。本研究基于群体药代动力学理论对首发精神分裂症患者使用奥氮平系统治疗，保证患者血药浓度在适宜范围。后通过前脉冲抑制，高密度脑电图及眼球运动测查，对首发精神分裂症患者在治疗前、治疗中及治疗后的相关的听觉及视觉认知加工异常的指标进行测查，与药物疗效进行相关分析。.已经完善奥氮平群体药代动力学模型，该研究显示，性别，吸烟、合并感染、合并用药（舍曲林、氟西汀及当归龙荟胶囊）均影响奥氮平代谢，且通过模型将影响定量化。部分药效数据已经收集完毕，群体药代动力学/药效学模型已初步建立完毕，可以优化急性期给药策略及后期减药策略。神经电生理指标未收集整理完毕，尚未纳入最终模型。